Question 1

Has Daniel Einhorn received payments from drug or device companies?

Accepted Answer

Yes. Drug and device makers reported $578,406 in general payments to Daniel Einhorn across 548 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Question 2

Does a payment mean Daniel Einhorn did something wrong?

Accepted Answer

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Question 3

Where does this information about Daniel Einhorn come from?

Accepted Answer

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Company	Payments	Total
Novo Nordisk	128	$170,701
Lilly USA, LLC	175	$139,080
Abbott	66	$83,869
Intuity Medical Inc	7	$57,812
Corcept Therapeutics	26	$45,193
Johnson & Johnson	69	$23,608
Boehringer Ingelheim	19	$15,492
Sanofi-aventis U.S. LLC	16	$14,565
Eli Lilly	2	$5,250
AstraZeneca	6	$5,070
Vistapharm, Inc.	5	$4,250
Senseonics, Incorporated	2	$3,523
Lifescan, Inc.	4	$2,732
Janssen Scientific Affairs, LLC	3	$2,642
Zealand Pharma US, Inc.	4	$2,389
Bayer	1	$1,535
Esperion Therapeutics, Inc.	3	$284
Amgen(2 entities)	4	$195
Janssen Global Services, LLC	2	$67
Mannkind Corporation	1	$59
Insulet Corporation	2	$41
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	1	$20
Gilead	1	$16
Dexcom, Inc.	1	$13

Daniel Einhorn

Payments from drug & device makers

Who reported the general payments

How this compares

Other endocrinology, diabetes & metabolism in la Jolla